Mattson Financial Services LLC Trims Stock Position in Pfizer Inc. $PFE

Mattson Financial Services LLC lessened its position in shares of Pfizer Inc. (NYSE:PFE) by 62.9% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 26,089 shares of the biopharmaceutical company’s stock after selling 44,249 shares during the period. Mattson Financial Services LLC’s holdings in Pfizer were worth $665,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently bought and sold shares of the company. Curio Wealth LLC raised its position in shares of Pfizer by 36,600.0% in the second quarter. Curio Wealth LLC now owns 1,101 shares of the biopharmaceutical company’s stock worth $27,000 after buying an additional 1,098 shares in the last quarter. Bayforest Capital Ltd purchased a new stake in shares of Pfizer in the 1st quarter valued at about $28,000. Harbor Asset Planning Inc. bought a new stake in shares of Pfizer during the 2nd quarter valued at about $29,000. Howard Hughes Medical Institute purchased a new position in shares of Pfizer during the second quarter worth about $30,000. Finally, Darwin Wealth Management LLC bought a new position in shares of Pfizer in the second quarter worth approximately $32,000. 68.36% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several equities research analysts have issued reports on the stock. Sanford C. Bernstein reiterated a “market perform” rating and set a $30.00 target price on shares of Pfizer in a research report on Friday, October 31st. Wall Street Zen lowered shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Sunday, September 28th. Morgan Stanley lowered their price target on Pfizer from $32.00 to $28.00 and set an “equal weight” rating on the stock in a research report on Friday, December 12th. Bank of America cut their price objective on Pfizer from $29.00 to $28.00 and set a “neutral” rating for the company in a report on Monday, December 15th. Finally, HSBC reissued a “buy” rating and set a $29.00 price objective on shares of Pfizer in a report on Wednesday, December 10th. Two analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, twelve have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Pfizer has a consensus rating of “Hold” and an average target price of $28.06.

Pfizer Stock Down 0.4%

PFE opened at $24.99 on Tuesday. Pfizer Inc. has a 12 month low of $20.92 and a 12 month high of $27.69. The company has a current ratio of 1.28, a quick ratio of 0.97 and a debt-to-equity ratio of 0.62. The business’s 50-day moving average price is $25.16 and its 200-day moving average price is $24.89. The company has a market cap of $142.07 billion, a P/E ratio of 14.53 and a beta of 0.46.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.87 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.79 by $0.08. The business had revenue of $16.65 billion for the quarter, compared to analyst estimates of $16.94 billion. Pfizer had a return on equity of 20.17% and a net margin of 15.65%.Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. On average, equities analysts expect that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 6th. Shareholders of record on Friday, January 23rd will be issued a $0.43 dividend. The ex-dividend date is Friday, January 23rd. This represents a $1.72 annualized dividend and a yield of 6.9%. Pfizer’s dividend payout ratio (DPR) is 100.00%.

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.